Abstract #300074

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2002 Program page
JSM 2002 Abstract #300074
Activity Number: 166
Type: Topic Contributed
Date/Time: Tuesday, August 13, 2002 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section*
Abstract - #300074
Title: Validation in High Throughput Screening
Author(s): David Stock*+
Affiliation(s): Bristol-Myers Squibb Company
Address: , , , ,
Keywords:
Abstract:

High throughput screening (HTS) involves the rapid testing of compounds against biological targets. The increasing demand for HTS services, and the scarcity of resources, has made it critical that every screen be properly validated before being put into production. From a statistical perspective, single-point screening assays, or primary screens, present the greatest challenge. In a primary screen the activity of a compound is judged by its performance at a single concentration. Typically, the activity of the compound is measured relative to the activity of positive and negative controls. Since primary screens differ from typical bioassays in a number of ways, they require different validation procedures. This talk outlines experimental procedures and statistical analyses for the validation of primary screens.

  • The address information is for the authors that have a + after their name.
  • Authors who are presenting talks have a * after their name.

Back to the full JSM 2002 program

JSM 2002

For information, contact meetings@amstat.org or phone (703) 684-1221.

If you have questions about the Continuing Education program, please contact the Education Department.

Revised March 2002